Glucagon
Glucagon is a 29-amino acid peptide hormone primarily secreted by alpha cells in the pancreatic islets of Langerhans. It plays a critical role in glucose homeostasis, particularly in elevating blood glucose levels during fasting or prolonged starvation. Unlike insulin, glucagon promotes hyperglycemia through hepatic glycogenolysis (breakdown of glycogen), gluconeogenesis (synthesis of glucose from non-carbohydrate precursors), and mobilization of fatty acids from adipose tissue.
The secretion of glucagon is regulated by physiological stimuli and inhibitors. It is stimulated by hypoglycemia, amino acids, epinephrine, norepinephrine, cortisol, and growth hormone, and inhibited by hyperglycemia, insulin, and somatostatin. Glucagon acts by binding to G-protein coupled receptors (GPCR) in hepatocytes, activating adenylyl cyclase, producing cyclic AMP (cAMP), and subsequently activating protein kinase A (PKA). Activated PKA phosphorylates glycogen phosphorylase kinase, catalyzing glycogen breakdown into glucose-1-phosphate, subsequently converted into glucose, thereby elevating plasma glucose levels.
Glucagonoma is a rare neuroendocrine tumor of the pancreas, characterized by autonomous excessive secretion of glucagon. Clinically, glucagonoma presents symptoms such as new-onset diabetes mellitus or hyperglycemia, significant weight loss, necrolytic migratory erythema, glossitis, angular stomatitis, venous thromboembolism (deep vein thrombosis and pulmonary embolism), and onychodystrophy.
Diagnosis of glucagonoma involves markedly elevated fasting plasma glucagon levels, typically above 500 pg/mL. Mild elevations of glucagon levels may occur in diabetes mellitus, diabetic ketoacidosis, and Cushing’s syndrome. Imaging studies, such as abdominal CT or MRI, are recommended to localize and characterize the glucagon-secreting tumors.
- As aid in diagnosis of Glucagonoma
- Useful in the monitoring of Cushing’s syndrome, diabetes mellitus, and diabetic ketoacidosis
Markedly elevated glucagon levels (>500 pg/mL) strongly indicate glucagonoma.
Increased in:
- Glucagonoma
- Diabetes mellitus
- Cushing’s syndrome
- Chronic renal failure
- Acute pancreatitis
- Severe stress
Decreased in:
- Pancreatic insufficiency
- Insulinoma
- Hypopituitarism
70 – 160 pg/mL
Fasting plasma (EDTA tube).
Stability
- Ambient: 3-5 days
- Refrigerated: 7 days
- Frozen: 90 days
- Biomark Med. 2016 Nov;10(11):1141-1151. [PMID: 27611762]
- Int J Dermatol. 1979 Jan-Feb;18(1):17-22. [PMID: 216645]
- Am J Med. 1987 May 29;82(5B):25-36. [PMID: 2884877]
- Oncotarget. 2016 Nov 15;7(46):74415-74426. [PMID: 27769070]
- Endocr Pathol. 2024 Dec;35(4):354-361. [PMID: 39331358]
- Diabetes Obes Metab. 2011 Oct;13 Suppl 1:151-7. [PMID: 21824269]